Analysis for REGN

📈 Growth & Financial Trajectory

The eight-quarter sequence shows modest revenue growth from start to end. Start quarter Q2 2024 revenues of $3.547B rising to $3.605B in Q1 2026, a ~1.6% gain, while net income declined from about $1.432B to $0.727B, ~49% lower. The period includes a peak in Q2 2025 with strong profitability (net income around $1.392B and operating margin near 41%), followed by softer results in late 2025 and early 2026. The trajectory is uneven but the company sustained positive operating cash flow throughout.

💰 Margins & Cash Flow

Operating margins ranged roughly from the high teens to the low 40s, averaging around 27%. The mid-2025 surge produced a peak margin, with net income margin fluctuating between roughly 21%–39% across quarters. Cash flow from operating activities remained positive in every quarter, with notable bursts of $1.62B in Q2 2025 and $1.08B in Q1 2026, signaling durable cash generation even as quarterly earnings swung.

🛡️ Balance Sheet & Liquidity

Balance sheet strength is evident: equity around $30.0–$31.6B and current assets near $18B against current liabilities of roughly $3.6–$4.4B, yielding liquidity well above 3x. Liabilities are modest relative to equity (debt-to-equity ~0.25–0.3). No material liquidity risk observed.

⚠️ Key Drivers & Risks

• Drivers: Biologic/drug development momentum and steady operating cash flow supporting R&D and pipeline.
• Risks: Revenue concentration and regulatory/patent cycles; cyclicity and competition sensitivity to approvals and launches.